The latest price target for Sutro Biopharma (NASDAQ:STRO) was reported by HC Wainwright & Co. on March 17, 2025. The analyst firm set a price target for $2.00 expecting STRO to rise to within 12 months (a possible 121.14% upside). 26 analyst firms have reported ratings in the last year.

The latest analyst rating for Sutro Biopharma (NASDAQ:STRO) was provided by HC Wainwright & Co., and Sutro Biopharma downgraded their neutral rating.

There is no last upgrade for Sutro Biopharma

The last downgrade for Sutro Biopharma Inc happened on March 17, 2025 when HC Wainwright & Co. changed their price target from $12 to $2 for Sutro Biopharma Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sutro Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sutro Biopharma was filed on March 17, 2025 so you should expect the next rating to be made available sometime around March 17, 2026.

While ratings are subjective and will change, the latest Sutro Biopharma (STRO) rating was a downgraded with a price target of $12.00 to $2.00. The current price Sutro Biopharma (STRO) is trading at is $0.90, which is out of the analyst’s predicted range.